Eva Scientific
Develops decellularization and recellularization bioreactors for whole-organ tissue engineering, enabling bioartificial organ production for research and production processes.
- CEO / Founder
- Andreas Kaasi
- Team Size
- 11-50
- Stage
- Active
- Total Funding
- R$1.14K
- Latest Round
- Grant
- Key Investors
- FAPESP
Technology & Products
Key Products
Eva™ decellularization and recellularization bioreactor; Luxor™ Biorreator; Eva™ Cairo Software de Biorreatores
Technological Advantage
Proprietary bioreactor technology for controlled tissue engineering processes, enabling research and production applications.
Differentiation
Value Proposition
Provides controlled bioreactor systems for decellularizing and recellularizing whole organs (e.g., rat livers, porcine tracheas), accelerating tissue engineering research and potential organ production.
How They Differentiate
Focus on whole-organ bioreactor systems for decellularization and recellularization, distinct from typical cell-based bioprinters.
Market & Competition
Target Customers
Research institutions, universities, biotech companies
Industry Verticals
Biotechnology; Medical Research; Tissue Engineering
Growth & Milestones
Growth Metrics
Ranked #1 in the 100 Open Startups Ranking in the category 'Top 5 Biotech'.
Major Milestones
Installed Eva™ bioreactor at Federal University of Rio Grande do Sul in February 2017; Strategic restructuring in 2023 to expand from research-only to research and production applications; Ranked #1 in Top 5 Biotech category in Ranking 100 Open Startups
Notable Customers
Federal University of Rio Grande do Sul